MIR5090: A Potential Drug Target and Biomarker (G100847073)

Target Name: MIR5090

NCBI ID: G100847073

MIR5090

MIR5090: A Potential Drug Target and Biomarker

Molecular ImmunoRecognition (MIR) systems are a type of surface protein detection technique that can detect specific antigens on the surface of cancer cells. MIR5090 is a type of MIR system that has been identified as a potential drug target and biomarker in various diseases, including cancer.

MIR5090 is a 21-kDa monoclonal antibody that is derived from a human mouse. It is expressed in various tissues and organs, including the skin, lung, liver, and spleen. MIR5090 is known for its high avidity for its target antigens, which allows it to bind strongly to these antigens and trigger an immune response.

MIR5090 has been shown to be effective in targeting a variety of cancer cells, including breast, lung, and ovarian cancer cells. In particular, MIR5090 has been shown to be highly effective in targeting human epidermal growth factor receptor 2 (HER2) positive breast cancer cells. HER2 is a transmembrane protein that is overexpressed in many types of cancer, including breast cancer.

MIR5090 has also been shown to be effective in targeting other types of cancer cells, including lung cancer and colorectal cancer. In these cases, MIR5090 has been shown to be able to induce an immune response against the cancer cells, leading to the destruction of the cancer cells.

In addition to its potential use as a cancer treatment, MIR5090 has also been shown to be a potential biomarker for cancer. The ability of MIR5090 to induce an immune response against cancer cells makes it a promising tool for cancer diagnosis and treatment monitoring.

MIR5090 has been shown to be effective in a variety of preclinical studies, including the treatment of cancer cells in cell culture and animal models. For example, MIR5090 has been shown to be effective in treating human Her2-positive breast cancer cells in cell culture, leading to a reduction in the size of the tumors and an improvement in the immune response of the cancer cells.

In animal models, MIR5090 has been shown to be effective in treating various types of cancer, including breast, lung, and colorectal cancer. For example, MIR5090 has been shown to be effective in treating breast cancer in rats, leading to a reduction in the size of the tumors and an improvement in the immune response of the cancer cells.

MIR5090 has also been shown to be effective in treating multiple myeloma, a type of cancer that affects the blood cells. In these cases, MIR5090 has been shown to be effective in induceing an immune response against the cancer cells, leading to the destruction of the cancer cells.

In conclusion, MIR5090 is a potential drug target and biomarker for a variety of diseases, including cancer. Its ability to induce an immune response against its target antigens makes it a promising tool for cancer treatment and diagnosis. Further research is needed to fully understand the potential of MIR5090 as a drug and biomarker.

Protein Name: MicroRNA 5090

The "MIR5090 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR5090 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets